Efficacy and safety of treatment with omalizumab for chronic spontaneous urticaria: A systematic review for the EAACI Biologicals Guidelines (2020)
Attributed to:
Cutaneous Immunology
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1111/all.14547
PubMed Identifier: 32767573
Publication URI: http://europepmc.org/abstract/MED/32767573
Type: Journal Article/Review
Parent Publication: Allergy
Issue: 1
ISSN: 0105-4538